Researchers identify drug target to treat sleeping sickness

April 06, 2000

Johns Hopkins researchers have discovered a new metabolic pathway in a parasite that could lead to drugs for treating so-called African sleeping sickness. The discovery, reported in the April 7 issue of Science, provides hope for the estimated 500,000 people who are fatally infected with the African trypanosome.

"There are no good drugs to treat this disease," says Paul T. Englund, Ph.D., a professor of biological chemistry at Johns Hopkins School of Medicine and principal investigator of the study. "The one drug out there is so toxic that it sometimes even kills people. The newly discovered pathway is a potential target for development of new drugs."

The immune system is particularly bad at fighting sleeping sickness, a major health problem in sub-Saharan Africa, because the parasite responsible is a master of disguise, Englund says. Throughout its lifetime, the parasite coats its surface with as many as 1,000 different proteins. By the time the immune system recognizes the intruder and starts making antibodies to destroy it, the parasite is already changing its coat so it can hide. This constant coat swapping makes it impossible to develop a vaccine for the disease, and researchers also have not been successful in developing drugs.

For several years, researchers have known that the protein coats are anchored to the parasite's cell surface by GPI anchors (glycosyl phosphatidylinositol anchors). These anchors contain myristate, a rather short fatty acid. Researchers haven't figured out, however, where the parasite obtains this anchor material. This fatty acid is rare in blood, and previous work had shown that it is not made in the parasite. Secondly, the researchers wondered, why did the anchor contain myristate, an uncommon fatty acid?

To examine the question, Yasu S. Morita, a predoctoral fellow in Englund's lab, tested whether the parasite would make GPI anchors with a shorter fatty acid. In test tube studies, he discovered that when he offered a shorter fatty acid to the African trypanosome, the parasite efficiently elongated it and made it into myristate. The researchers realized that the long-held assumption that the parasite did not make this material might be false. Otherwise, why would the parasite have such an efficient elongating system?

Using radioactive labels, the researchers reanalyzed the parasite's biochemical makeup and found that indeed the parasite did make myristate but not in the conventional way. While most cells make a variety of fatty acids for general use in all types of membranes as well as for energy storage, trypanosomes only make myristate, and they only use it to make GPI anchors. In another experiment, the researchers tested the effects of a fatty acid inhibitor, thiolactomycin, on the parasite. In test tube studies, they found that thiolactomycin successfully inhibited myristate synthesis and killed the parasite.

"We are not going to be able to use thiolactomycin as a drug to treat sleeping sickness because it is needed in high concentrations to have an effect," says Englund. "But this is a new and very interesting pathway in a parasite that is a potential drug target. Derivatives of thiolactomycin might have potential."

Sleeping sickness is a fatal disease that is prevalent in much of tropical Africa. Depending upon the trypanosome type, an individual dies in a few months or a couple of years. Fatigue, tremors, fever, inflammation of the lymph nodes, and involvement of the brain and spinal cord leading to profound lethargy, paralysis, coma and death characterize the disease. Human infections are transmitted by the tsetse fly.
-end-
The other author of the study is Kimberly S. Paul, Ph.D., a postdoctoral fellow in the Department of Biological Chemistry at Johns Hopkins School of Medicine.

Johns Hopkins Medicine

Related Immune System Articles from Brightsurf:

How the immune system remembers viruses
For a person to acquire immunity to a disease, T cells must develop into memory cells after contact with the pathogen.

How does the immune system develop in the first days of life?
Researchers highlight the anti-inflammatory response taking place after birth and designed to shield the newborn from infection.

Memory training for the immune system
The immune system will memorize the pathogen after an infection and can therefore react promptly after reinfection with the same pathogen.

Immune system may have another job -- combatting depression
An inflammatory autoimmune response within the central nervous system similar to one linked to neurodegenerative diseases such as multiple sclerosis (MS) has also been found in the spinal fluid of healthy people, according to a new Yale-led study comparing immune system cells in the spinal fluid of MS patients and healthy subjects.

COVID-19: Immune system derails
Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction - rather, the immune response is caught in a continuous loop of activation and inhibition.

Immune cell steroids help tumours suppress the immune system, offering new drug targets
Tumours found to evade the immune system by telling immune cells to produce immunosuppressive steroids.

Immune system -- Knocked off balance
Instead of protecting us, the immune system can sometimes go awry, as in the case of autoimmune diseases and allergies.

Too much salt weakens the immune system
A high-salt diet is not only bad for one's blood pressure, but also for the immune system.

Parkinson's and the immune system
Mutations in the Parkin gene are a common cause of hereditary forms of Parkinson's disease.

How an immune system regulator shifts the balance of immune cells
Researchers have provided new insight on the role of cyclic AMP (cAMP) in regulating the immune response.

Read More: Immune System News and Immune System Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.